These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34527579)

  • 1. Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML.
    Lopez A; Patel S; Geyer JT; Racchumi J; Chadburn A; Simonson P; Ouseph MM; Inghirami G; Mencia-Trinchant N; Guzman ML; Gomez-Arteaga A; Lee S; Desai P; Ritchie EK; Roboz GJ; Tam W; Kluk MJ
    Front Oncol; 2021; 11():701318. PubMed ID: 34527579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in
    Patkar N; Kodgule R; Kakirde C; Raval G; Bhanshe P; Joshi S; Chaudhary S; Badrinath Y; Ghoghale S; Kadechkar S; Khizer SH; Kannan S; Shetty D; Gokarn A; Punatkar S; Jain H; Bagal B; Menon H; Sengar M; Khattry N; Tembhare P; Subramanian P; Gujral S
    Oncotarget; 2018 Nov; 9(93):36613-36624. PubMed ID: 30564301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
    Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
    Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia.
    Patel SS; Pinkus GS; Ritterhouse LL; Segal JP; Dal Cin P; Restrepo T; Harris MH; Stone RM; Hasserjian RP; Weinberg OK
    Am J Hematol; 2019 Aug; 94(8):921-928. PubMed ID: 31148220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Laboratory Validation and Implementation of Quantitative, Real-Time PCR-based Detection of NPM1 Type A Mutation.
    Racchumi J; Tam W; Kluk MJ
    Clin Lab; 2020 Dec; 66(12):. PubMed ID: 33337831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia.
    Ottone T; Ammatuna E; Lavorgna S; Noguera NI; Buccisano F; Venditti A; Giannì L; Postorino M; Federici G; Amadori S; Lo-Coco F
    J Mol Diagn; 2008 May; 10(3):212-6. PubMed ID: 18403613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
    Brar N; Lawrence L; Fung E; Zehnder JL; Greenberg PL; Mannis GN; Zhang TY; Gratzinger D; Oak J; Silva O; Kurzer J; Tan B; Menke JR; Fernandez-Pol S
    Am J Clin Pathol; 2024 Sep; 162(3):269-281. PubMed ID: 38643353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.
    Du Pisani LA; Shires K
    Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):106-14. PubMed ID: 26183674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A surrogate marker to detect nucleophosnim (NPM1) gene mutations in the cytoplasm of acute myeloid leukemia (AML) blast cells in 30 adult Iraqi patients.
    Al-Husseinawi EK
    Ann Saudi Med; 2013; 33(6):539-46. PubMed ID: 24413856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleophosmin mutation analysis in acute myeloid leukaemia: Immunohistochemistry as a surrogate for molecular techniques.
    Chopra A; Soni S; Pati H; Kumar D; Diwedi R; Verma D; Vishwakama G; Bakhshi S; Kumar S; Gogia A; Kumar R
    Indian J Med Res; 2016 Jun; 143(6):763-768. PubMed ID: 27748301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.
    Mencia-Trinchant N; Hu Y; Alas MA; Ali F; Wouters BJ; Lee S; Ritchie EK; Desai P; Guzman ML; Roboz GJ; Hassane DC
    J Mol Diagn; 2017 Jul; 19(4):537-548. PubMed ID: 28525762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I diagnose and treat NPM1-mutated AML.
    Falini B; Brunetti L; Martelli MP
    Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.
    Blombery P; Jones K; Doig K; Ryland G; McBean M; Thompson E; Yannakou CK; Westerman D
    Arch Pathol Lab Med; 2018 May; 142(5):606-612. PubMed ID: 29425073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia.
    Dai Q; Ren Y
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):205-11. PubMed ID: 23591014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker.
    Alizad Ghandforoush N; Chahardouli B; Rostami S; Ghadimi H; Ghasemi A; Alimoghaddam K; Ghavamzadeh A; Nadali F
    Int J Hematol Oncol Stem Cell Res; 2016 Jul; 10(3):147-52. PubMed ID: 27489590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.